Discovery of Selective and Potent Inhibitors of Gram-Positive Bacterial Thymidylate Kinase (TMK)
Citations Over TimeTop 16% of 2012 papers
Abstract
Thymidylate kinase (TMK) is an essential enzyme in bacterial DNA synthesis. The deoxythymidine monophosphate (dTMP) substrate binding pocket was targeted in a rational-design, structure-supported effort, yielding a unique series of antibacterial agents showing a novel, induced-fit binding mode. Lead optimization, aided by X-ray crystallography, led to picomolar inhibitors of both Streptococcus pneumoniae and Staphylococcus aureus TMK. MICs < 1 μg/mL were achieved against methicillin-resistant S. aureus (MRSA), S. pneumoniae, and vancomycin-resistant Enterococcus (VRE). Log D adjustments yielded single diastereomers 14 (TK-666) and 46, showing a broad antibacterial spectrum against Gram-positive bacteria and excellent selectivity against the human thymidylate kinase ortholog.
Related Papers
- → Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil: Is it time to move forward?(2008)95 cited
- → Tumor Cell Responses to Inhibition of Thymidylate Synthase(1988)6 cited
- → Enhancement of thymidylate synthase inhibition(1993)5 cited
- Current status of thymidylate synthase inhibitors in cancer therapy(2005)
- → The therapeutic efficacy of thymidylate synthase on pemetrexed treatment of lung adenocarcinoma(2017)